 |
Delivering
Performance Improvement Findings from DiabetesE |
| |
Third National Report. 91-page PDF (Innove,
UK) |
| |
|
|
Next
National DiabetesE Report |
| |
If your PCT has yet to use DiabetesE or would
like some support for undertaking a DiabetesE assessment, please
contact Barbara Wright (Innove, UK) |
| |
|
|
Health
Experts Call for New Strategies to Combat Alarming Rise in Diabetes |
| |
Johnson & Johnson Diabetes Institute Launched
as New Research Suggests Improved Patient Education May Play Key
Role in Halting Escalating Disease in the EMEA Region (Market Watch) |
| |
|
|
New
guidelines for blood donors |
| |
Diabetes UK welcomes a change in blood service
guidelines allowing some people with Type 2 diabetes to now donate
blood if they wish to (Diabetes UK ) |
| |
|
|
Controlling
blood glucose and reducing the risk of cardiovascular disease
in type 2 diabetes |
| |
Guidelines and performance measures should be
based on the best available evidence and highlight strategies that
benefit patients. For type 2 diabetes, this means using interventions
that not only reduce blood glucose levels, but are also proven
to reduce the risk of cardiovascular (CV) events and/or improve
wellbeing (NPC, MeReC, NHS, UK) |
| |
|
|
American
Diabetes Association Celebrates Historic Victory for Americans
With Disabilities |
| |
President Bush Signs Landmark Civil Rights Legislation
Into Law (Market Watch) |
| |
|
|
Bringing
diabetes to light: encouraging citizens to raise awareness and
protect future generations |
| |
Theme for 2008 World Diabetes Day – November
14 – is “Diabetes in Children and Adolescents” (International Diabetes Federation) |
| |
|
|
New
Diabetes Drug Works Well in Trial |
| |
The drug, liraglutide, is a laboratory-made
version of glucagon-like peptide-1 (GLP-1), a hormone produced
by the body (Washington Post, USA) |
| |
|
|
Array
BioPharma Presents Positive Preclinical Data on Its Glucokinase
Activators in Type 2 Diabetes |
| |
The data showed that ARRY-403 (a novel small
molecule glucokinase activator) demonstrated potent, highly glucose-blood-level
dependent, control of both fasting and non-fasting glucose concentrations.
Based on these and other results, Array plans to advance ARRY-403
into human clinical studies in the first half of 2009 (Market Watch) |
| |
|
|
Takeda
files alogliptin/Actos diabetes combo with FDA |
| |
Takeda Pharmaceutical Co has submitted a New
Drug Application to US regulators to get marketing approval for
its new dipeptidyl peptidase-4 inhibitor SYR-322 and the blockbuster
Actos combined in a single tablet for the treatment of type 2 diabetes
(PharmaTimes) |
| |
|
|
Clean
homes and diabetes risk |
| |
These results have been over-interpreted by
the newspapers. It is not yet clear to what extent these genetically
modified mice are representative of the development of an autoimmune
condition such as diabetes in humans (Behind the Headlines, NHS
Choices, UK) |
| |
|
